Form 4: Theravance Biopharma CEO Rick Winningham Reports Share Transactions
SEC Form 4 Filing
CEO Rick Winningham reports acquisition and gifting of Theravance Biopharma shares.
Summary
- On March 15, 2024, Rick E. Winningham, CEO of Theravance Biopharma, acquired 2,704 ordinary shares at $8.64 per share under the company's equity incentive plan.
- Winningham gifted 7,000 ordinary shares and gifted 3,900 shares to a custodial account under the Uniform Transfer to Minors Act (UTMA).
- Following these transactions, Winningham directly owns 1,550,573 ordinary shares and indirectly owns 3,900 shares as custodian and 92,567 shares by trust.
Sentiment
Score: 6
Explanation: Neutral sentiment as the document simply reports transactions. The acquisition could be seen as slightly positive, but the gifting is neutral.
Positives
- The acquisition of shares by the CEO demonstrates confidence in the company's future.
Industry Context
Form 4 filings are standard practice for reporting insider transactions and provide transparency to investors.
Key Dates
| Date | Description |
|---|---|
| 03/15/2024 | Date of share acquisition and gifting transactions. |
| 03/19/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.